NantHealth Inc. (NH)

0.62
NASDAQ : Technology Services
Prev Close 0.69
Day Low/High 0.62 / 0.69
52 Wk Low/High 0.62 / 4.05
Avg Volume 168.70K
Exchange NASDAQ
Shares Outstanding 109.49M
Market Cap 71.77M
EPS -1.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NantHealth® Advances Clinician Productivity And Critical Patient Information Access With Enhancements To DeviceConX™

NantHealth® Advances Clinician Productivity And Critical Patient Information Access With Enhancements To DeviceConX™

NantHealth (NASDAQ: NH), a leader in breakthrough cancer research and data solutions that improve patient care and lower healthcare costs, today announced updates to its Connected Care portfolio of medical device integration (MDI) products, including...

NantHealth®, B. Braun Australia, GE Healthcare And IProcedures Join Forces To Bridge Connectivity Gap Between Patient Devices, Data And Medical Records At The Healthcare Information And Management Systems Society (HIMSS) Asia Pacific Conference

NantHealth®, B. Braun Australia, GE Healthcare And IProcedures Join Forces To Bridge Connectivity Gap Between Patient Devices, Data And Medical Records At The Healthcare Information And Management Systems Society (HIMSS) Asia Pacific Conference

NantHealth (NASDAQ: NH), a leader in breakthrough cancer research and solutions to improve patient care and lower healthcare costs, today announced a collaboration with B.

NantHealth To Report 2018 Third-Quarter Financial Results And Host Conference Call On Thursday, November 15

NantHealth To Report 2018 Third-Quarter Financial Results And Host Conference Call On Thursday, November 15

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 third quarter on Thursday, November 15, 2018, after market close.

NantHealth And NantOmics Present Four Research Papers Demonstrating Advancements In Cancer Diagnostics With NantHealth's GPS Cancer® And Liquid GPS™

NantHealth And NantOmics Present Four Research Papers Demonstrating Advancements In Cancer Diagnostics With NantHealth's GPS Cancer® And Liquid GPS™

Significant developments in cancer research were presented by NantHealth (NASDAQ: NH) and NantOmics at the ESMO conference in Munich, Germany this week.

NantHealth Announces Appointment Of Two Senior Executives To Lead Strategy, Business Development, And Global Sales

NantHealth Announces Appointment Of Two Senior Executives To Lead Strategy, Business Development, And Global Sales

NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, announced new executive appointments to lead the company's strategy and business development as well as global sales.

Using The Technology That Powers GPS Cancer™, Scientists Have Developed Fresh Insights Into The Driving Mechanisms Of A Rare Skin Cancer

Using The Technology That Powers GPS Cancer™, Scientists Have Developed Fresh Insights Into The Driving Mechanisms Of A Rare Skin Cancer

New, peer-reviewed research utilizing NantOmics technology, which powers NantHealth's (NASDAQ: NH) GPS Cancer ® is giving scientists fresh insights into the driving mechanisms behind a form of rare skin cancer as well as therapies to treat patients.

NantHealth Reports 2018 Second-Quarter Financial Results

NantHealth Reports 2018 Second-Quarter Financial Results

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its second quarter ended June 30, 2018.

NantHealth To Report 2018 Second-Quarter Financial Results And Host Conference Call On Thursday, August 9

NantHealth To Report 2018 Second-Quarter Financial Results And Host Conference Call On Thursday, August 9

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 second quarter on Thursday, August 9, 2018, after market close.

SHAREHOLDER ALERT: Hynes Keller & Hernandez, LLC Announces Investigation Of NantHealth, Inc. (NH) And FleetCor Technologies, Inc. (FLT)

SHAREHOLDER ALERT: Hynes Keller & Hernandez, LLC Announces Investigation Of NantHealth, Inc. (NH) And FleetCor Technologies, Inc. (FLT)

NEW YORK, July 31, 2018 /PRNewswire/ --  Hynes Keller & Hernandez, LLC is investigating potential claims against the Board of Directors of NantHealth, Inc.

NantHealth Unveils New Collaboration Tools - Provider Initiated Document Exchange And Authorization Appeals

NantHealth Unveils New Collaboration Tools - Provider Initiated Document Exchange And Authorization Appeals

NantHealth, Inc. (NASDAQ: NH) announced two exciting new product launches - Provider Initiated Document Exchange and Authorization Appeals - on the nation's leading payer-provider collaboration platform, NaviNet® Open, at the 2018 AHIP Institute and Expo.

NantHealth To Present And Exhibit On The Convergence Of Precision Medicine And Value-Based Care At America's Health Insurance Plans (AHIP) Institute & Expo 2018

NantHealth To Present And Exhibit On The Convergence Of Precision Medicine And Value-Based Care At America's Health Insurance Plans (AHIP) Institute & Expo 2018

NantHealth (NASDAQ: NH), a next-generation healthcare company, will exhibit and present at America's Health Insurance Plans ( AHIP) Institute & Expo 2018 taking place June 20-22, 2018 at the San Diego Convention Center in San Diego, CA at booth #824.

NantHealth And NantOmics To Present Data On The Frequency Of Non-Expressed Variants Tested By Standard NGS Panel At The American Society Of Clinical Oncology (ASCO) 2018 Annual Meeting

NantHealth And NantOmics To Present Data On The Frequency Of Non-Expressed Variants Tested By Standard NGS Panel At The American Society Of Clinical Oncology (ASCO) 2018 Annual Meeting

NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks...

NantHealth And NantOmics To Present Patterns Of Immune Checkpoint Molecules In Relation To PD-L1 Expression At The American Society Of Clinical Oncology (ASCO) 2018 Annual Meeting

NantHealth And NantOmics To Present Patterns Of Immune Checkpoint Molecules In Relation To PD-L1 Expression At The American Society Of Clinical Oncology (ASCO) 2018 Annual Meeting

NantWorks, LLC today announced that its affiliate companies, NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company and NantOmics, LLC, the leader in molecular analysis and a member of the NantWorks...

NantHealth Unveils Liquid GPS™, Powerful Next-Generation Tool For Blood-Based Tumor Profiling And Quantitative Monitoring

NantHealth Unveils Liquid GPS™, Powerful Next-Generation Tool For Blood-Based Tumor Profiling And Quantitative Monitoring

NantHealth, Inc. (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, unveiled Liquid GPS™ a powerful next-generation tool for blood-based tumor profiling and quantitative monitoring.

NantOmics Announces Study Showing Signature Analysis That Reveals Three Distinct Classifications Of Skin Cancer Known As Sebaceous Carcinoma

NantOmics Announces Study Showing Signature Analysis That Reveals Three Distinct Classifications Of Skin Cancer Known As Sebaceous Carcinoma

NantOmics, LLC, the leader in molecular analyses and a member of the NantWorks ecosystem of companies, announced today the publication of peer-reviewed research defining for the first time three distinct classifications of sebaceous carcinoma, a rare and...

NantHealth To Present At The Bank Of America Merrill Lynch Health Care Conference 2018 On May 17

NantHealth To Present At The Bank Of America Merrill Lynch Health Care Conference 2018 On May 17

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that its management will be presenting at the Bank of America Merrill Lynch 2018 Health Care Conference on Thursday, May 17, 2018, at...

NantHealth Showcases And Presents Its Portfolio Of Medical Device Integration (MDI) Products To Provide Current And Future Insights To Patient Care At The Largest E-Health Event In Scandinavia

NantHealth Showcases And Presents Its Portfolio Of Medical Device Integration (MDI) Products To Provide Current And Future Insights To Patient Care At The Largest E-Health Event In Scandinavia

NantHealth (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, showcased their Connected Care solutions at Vitalis, the largest e-health event in Scandinavia.

CORRECTING And REPLACING NantHealth Reports 2018 First-Quarter Financial Results

CORRECTING And REPLACING NantHealth Reports 2018 First-Quarter Financial Results

Changes have been made to the "Supplemental Revenue Schedule" and "Non-GAAP Net Loss and Non-GAAP Net Loss Per Share" financial tables.

NantHealth And NantOmics Announce Publication Of Study Highlighting High Error Rates In Tumor-Only Sequencing For Cancer Treatment

NantHealth And NantOmics Announce Publication Of Study Highlighting High Error Rates In Tumor-Only Sequencing For Cancer Treatment

NantHealth, Inc., (NASDAQ: NH), a leading next-generation, evidence-based, personalized healthcare company, and NantOmics, LLC, the leader in molecular diagnostics and a member of the NantWorks ecosystem of families, announced today joint results that...

NantHealth To Report 2018 First-Quarter Financial Results And Host Conference Call On Wednesday, May 9

NantHealth To Report 2018 First-Quarter Financial Results And Host Conference Call On Wednesday, May 9

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2018 first quarter on Wednesday, May 9, 2018, after market close.

NantHealth Reports 2017 Fourth-Quarter And Full-Year Financial Results

NantHealth Reports 2017 Fourth-Quarter And Full-Year Financial Results

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2017.

NantHealth To Report 2017 Fourth-Quarter And Full-Year Financial Results And Host Conference Call On Wednesday, March 14

NantHealth To Report 2017 Fourth-Quarter And Full-Year Financial Results And Host Conference Call On Wednesday, March 14

NantHealth, Inc. (NASDAQ-GS: NH), a next-generation, evidence-based, personalized healthcare company, today announced that it will report financial results for its 2017 fourth quarter and full year on Wednesday, March 14,...

NantHealth To Present On The Future Of Device Connectivity Across The Continuum Of Care At HIMSS18

NantHealth To Present On The Future Of Device Connectivity Across The Continuum Of Care At HIMSS18

NantHealth (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, will be exhibiting this year at the Healthcare Information & Management Systems Society Annual Conference & Exhibition...

Short Interest Moves 11.5% Lower For NH

Short Interest Moves 11.5% Lower For NH

The most recent short interest data has been released for the 01/12/2018 settlement date, which shows a 362,158 share decrease in total short interest for NantHealth Inc , to 2,775,639, a decrease of 11.54% since 12/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Tronc Sells Los Angeles Times After Battle With Shareholder

Tronc Sells Los Angeles Times After Battle With Shareholder

Tronc's No. 2 shareholder, billionaire Patrick Soon-Shiong, will pay $500 million and assume $90 million in pension liabilities to acquire the Los Angeles newspaper as well as The San Diego Union-Tribune.

Tronc Will Reportedly Sell Los Angeles Times for $500 Million

Tronc Will Reportedly Sell Los Angeles Times for $500 Million

Move would return Southern California paper to local control for first time in 18 years.

Commit To Buy NantHealth At $2.50, Earn 12.2% Annualized Using Options

Commit To Buy NantHealth At $2.50, Earn 12.2% Annualized Using Options

Investors eyeing a purchase of NantHealth Inc stock, but tentative about paying the going market price of $3.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 20 cents.

TheStreet Quant Rating: D- (Sell)